ISPE s Process Capability Team
|
|
- Lorin Barnett
- 6 years ago
- Views:
Transcription
1 4 September 7 INDUSTRY MATURITY IN THE ASSESSMENT AND USE OF PROCESS CAPABILITY Arne Zilian Head MS&T Processes & Standards Novartis Pharma AG Process Validation Statistics Conference 5 September 7 ISPE s Process Capability Team - Performance and Compliance Applications PQLI ISPE Process Capability Team - Statistical Considerations 3 - Maturity Model Development Team Goals (per Team Charter): To develop a position on process capability as a performance and/or compliance metric Reportable to FDA to support a risk-based inspection program as outlined in sections 75 to 76 of US Food and Drug Administration Safety and Innovation Act (FDASIA). Acceptable to industry, addressing challenges for implementation. To communicate this position & gain support for implementation across pharmaceutical companies via: A series of articles and/or white papers. Potential baseline guide. Sessions at ISPE and other meetings.
2 4 September 7 Goal: Improve Quality and Ensure Reliable Supply.. Performance and Compliance Applications. Self-audit of process performance helps to prioritize improvements Embed a product robustness review process in the organization (at site level/ supply chain end-to-end/ for overall product portfolio). Statistical Considerations. Process Capability is an easy and meaningful metric to capture and report but there are challenges: Real life is drastically different from textbook examples Difficult to predict failures using Cpk/Ppk Many failures are not related to Cpk/Ppk 3. Maturity Model Development. Such a model can be used to guide through the implementation journey Survey was conducted to assess where companies are today, where they want to be Common opportunities for improvement have been identified 3 Process Capability Indices: The Good, The Bad, and The Ugly ASTM defines process capability as the natural or inherent behavior of a stable process that is in a state of statistical control, which is achieved when the process exhibits no detectable patterns or trends. (ASTM E8). Statistical tools such as control charts are utilized in the determination of process capability, however capability indices are often commonly used. The Good: Dimensionless index which can be used to compare across products, attributes, etc. The Bad: Highly dependent on meaningful specifications and well-behaved data sets. The Ugly: Process Capability is not the whole story. Complexity associated with practical application of these tools limits their effectiveness as a compliance requirement. 4
3 4 September 7 Three Levels of Product Robustness Monitoring Rely on Associates with Product Understanding 3. Quarterly Portfolio Review Sr. Management Scorecard looking at all sites and products. End to End Product Reviews --Cross functional team across Drug Substance, Drug Product, Analytical, Stability and Quality --Deeper Statistical Analysis applied to Hot Spots Attribute X Drug Product Manufacturing Site -Approximately Monthly inter batch data reviews -Voice of the Process at the Shop Floor -Site Focused but also feeds data upward 5 Product Robustness Involves Many Elements Bika, D., Walsh, J., Nestor, T., and Allenspach, C. Product Robustness: A comprehensive Product Quality Strategy, AAPS Newsmagazine, p 6-9, August
4 4 September 7 Process Robustness Continuous Improvement Over Time Release Attributes Summary Low <. Medium.-.33 High >.33 Significant improvement in robustness performance observed over the past 5 years Example from Peter G. Millili, BMS. Y-axis: proportion of CQAs with high/medium/low Cpk 7 Statistical Considerations Gap between Reality and Textbook A simple interpretation of process capability metrics is often not possible Must understand details of the data, and how results will be used. Otherwise, actions may be improper! ISPE Discussion Paper focuses on: ) use of process capability for risk based decsions for action and ) identification and practical treatment of non-textbook situations 8 4
5 4 September 7 Using Ppk for Risk Based Decision for Action Select relevant CQA and IPC DRAFT Here risk is negligible hence no further action required. Here risk is acceptable hence no further action required. Further analysis required. Maybe action required to remediate risk. Maybe accept risk based on cross-functional review. 9 Statistical Considerations: Textbook Example Individual Value Process Capability Sixpack Report for Assay 3 I Chart UCL=3.73 _ X=99.5 LCL=94.36 LSL 96 Capability Histogram 98 4 USL LSL 95 USL 5 5. Moving Range Chart UCL=5.76 Normal Prob Plot AD:.565, P:.3 Moving Range.5 MR=.763. LCL= Last 5 Observations Capability Plot Values 4 StDev.563 Cp.7 Cpk.86 PPM StDev.57 Pp.9 Ppk.88 Cpm * PPM Observation 5 3 Specs 5
6 ISPE Process Validation Conference 4 September 7 Statistical Considerations - Reality Small data sets Small number of unique values, including case with many values less than LOQ Non-independence resulting from non-random use of sources of variability Non-normality based on process performance, not customer driven (clinically relevant) Process Shifts Due to Non Random Use of Sources of Variability Individual Value Moving Range Process Capability Sixpack Report for CQA I Chart Moving Range Chart UCL=.343 _ X=.338 LCL=.9853 UCL=.355 MR=.73 LCL= Capability Histogram USL Normal Prob Plot AD:., P: <.5.3 USL.3.3 Individual Value I Chart of CQA4 by Batch UCL=.33 _ X=.9755 Values Last 5 Observations 55 6 Observation 65 7 StDev.95 Cp * Cpk 3. PPM. Capability Plot Specs StDev.398 Pp * Ppk.7 Cpm * PPM Observation 6 36 LCL=
7 4 September 7 Process Shifts Due to Non Random Use of Sources of Variability Process Capability Sixpack Report for CQA3 I Chart Capability Histogram Time Series Plot of CQA3 Individual Value Moving Range Moving Range Chart UCL=.64 _ X=.583 LCL=8.55 UCL=.495 MR=.764 LCL= LSL USL 4 Normal Prob Plot AD:.64, P: <.5 LSL 8 USL 4 CQA Last 5 Observations Capability Plot 9 Values Observation 65 7 StDev.6769 Cp.48 Cpk.7 PPM 68.5 Specs StDev.975 Pp.3 Ppk.89 Cpm * PPM Index Data with underlying non-normal distribution Moving Range Individual Value Process Capability Sixpack Report for Tailings CQA 5 (kg) I Chart Moving Range Chart UCL=47.7 _ X=6. LCL=-5.3 UCL=38.67 MR=.84 LCL= Capability Histogram USL Normal Prob Plot AD: 9.7, P: <.5 USL 5 8 Moving Range Individual Value Process Capability Sixpack Report for Tailings CQA 5 (kg) Using Box-Cox Transformation With λ = I Chart 96 5 Moving Range Chart UCL=4.55 _ X=.539 LCL=.57 UCL=.47 MR=.757 LCL=.. Capability Histogram USL* 4. Normal Prob Plot AD:.4, P: USL* Values 5 5 Last 5 Observations StDev.49 Cp * Cpk.7 PPM Capability Plot StDev.48 Pp * Ppk.9 Cpm * PPM Values Last 5 Observations StDev.679 Cp * Cpk.68 PPM Transformed Capa Plot StDev.6969 Pp * Ppk.66 Cpm * PPM Observation 85 9 Specs Observation 85 9 Specs 4 7
8 4 September 7 Statistical Considerations - Other Topics Influence of Measurement Variability Manipulated Data Survey of Other Methods 5 Why a Maturity Model? As shown in the example, continuous improvement success comes after a multi- year effort. During the course of the program, Sponsor and workstream leaders may change Culture changes slowly Systems contribute to inertia New ways of working need to be implemented A compass is needed to find true north 6 8
9 4 September 7 What is a Maturity Model? A maturity model points out areas for improvement starting from a current ( ) level, going to a target level ( ) Level - Initial. Exclusively a business process, not in quality systems. Lacks some rigor. Ad hoc, reactive, driven by users or events. Level Repeatable. Proactive within some organizations/groups. Proactive but selectively applied. Level 3 Defined. Proceduralized. There are sets of defined and documented standard procedures established and subject to some degree of improvement over time. Level 4 Managed. Rolled out across sites, networks, organizational units and functions. Level 5 Optimizing. Proactive, integrated into the culture and operations management review. Comprehensive view of leading indicators and recurring root causes. 7 Maturity Matrix Consists of Nine Key Process Areas In order to use process capability and concept tools optimally, it is important to achieve a certain level of proficiency and/or clarity in 9 specific areas: Policy SOPs are established. Data Management a system for collecting, managing and accessing data. Frequency how often process capability indices are calculated. Basis for Specification manner in which specifications are developed and linked to clinical studies. Calculation Consistency use of process capability approach, calculations and metrics. Response thresholds with action required, attention is shifted to products with low capability. Organization Skill Set and Execution level of process capability knowledge across the organization. Risk-based Context part of an overall risk management framework. Commercialization sources of variability are well understood. Process capability at initial launch is high and site resources focus on continuous improvement. 8 9
10 4 September 7 ISPE Process Capability Maturity Model: Key Process Areas Optimization Commercialization Basis for Response Calculation Consistency Organization and Skill sets Policy Frequency Risk-based Approach Data Management Foundational For each key process area five levels of maturity are defined with detailed descriptions 9 Maturity Model Survey - biggest opportunities according to participating companies are Commercialization and Data Optimization Management Commercialization Big change planned: Lowest starting point Medium ambition Basis for Foundational Response Policy Calculation Consistency Risk-based Approach Big change planned: Low starting point High ambition Organization and Skill sets Frequency Publication submitted to Pharm Eng
11 4 September 7 Main Areas for Improvement Commercialization challenges - Small data set before/ after commercial launch - Little experience with applying process capability at this stage in the lifecycle survey responses: Majority of data is CQAs, some CPP data available., program is in early stages of maturity, starting to integrate risk based methods, using scale up models for site transfers and commercialization. (5 yrs)* Data Management challenges - Complex IT system landscape - Manual data management - Cost of IT system upgrade survey responses: Some databases are structured; some are manually entered/updated. Network roll-up not available (% manual) Product specific, may or may not be automated. (5 yrs)* On demand pull of capability data (5 yrs)* (*Number of years using Process Capability Measurements) KEY TAKE AWAYS Process Capability is only a small part of the story A sustainable business process is needed to be successful Textbooks are good to get started It takes years to reach maturity and some already got there!
12 4 September 7 ISPE PROCESS CAPABILITY COMMUNITY OF PRACTICE PERFORMANCE AND COMPLIANCE APPLICATIONS WORKSTREAM Peter Millili Team Lead, BMS Jason Orloff PharmStat Kevin Roberson ABC Labs Abizer I. Harianawala Ariad Julia O Neill Tunnell Consulting Abe Germansderfer SHL Philippe Cini Tunnell Consulting George Millili Roche Genentech STATISTICS WORKSTREAM Tara Scherder Team Lead, Synolo Stats James Crichton Cook Pharmica Mahesh Shivhare Novartis Andreas Dander Novartis Aaron Goerke Roche Genentech MATURITY MODEL WORKSTREAM Philippe Cini Team Lead, Tunnell Consulting Gretchen Allison Pfizer Gerald Leister Eli Lilly and Company Eda Ross Montgomery Shire Pharmaceuticals Julia O Neill Tunnell Consulting Mike Thomas Tunnell Consulting Eric Thostesen Janssen Pharmaceuticals Arne Zilian Novartis
Product Robustness: Reducing Variability and Ensuring Delivery of Superior Quality Products to Patients
Product Robustness: Reducing Variability and Ensuring Delivery of Superior Quality Products to Patients Dafni Bika, Jennifer Walsh and Tara Nestor Global Manufacturing Science and Technology Bristol-Myers
More informationDrug Product Continuous Process Verification A Case Study
Drug Product Continuous Process Verification A Case Study CASSS 2016 Summer CMC 19 July 2016 Tom Damratoski Bristol-Myers Squibb Director, Biologics Drug Product MS&T 1 Drug Product CPV In Practice - 3
More informationDaniel Y. Peng, Ph.D.
Using Process Capability to Enhance Product Quality Daniel Y. Peng, Ph.D. Senior Product Quality Reviewer Office of Process and Facility (OPF) OPQ/CDER/FDA IFPAC 2015 Annual Meeting Arlington, Virginia
More informationUnderstanding Variation and Statistical Process Control: Variation and Process Capability Calculations
Understanding Variation and Statistical Process Control: Variation and Process Capability Calculations www.nano4me.org 2017 The Pennsylvania State University Process Capability Calculations 1 Outline Variation
More informationStatistics in Validation. Tara Scherder CSO Supply, Arlenda, Inc
Statistics in Validation 05 Arlenda Tara Scherder CSO Supply, Arlenda, Inc IVT Validation Week Philadelphia, PA Oct 7,05 Agenda Evolution of Validation 0 FDA Guidance Why Use Statistics Stage Process Design
More informationProcess Performance Analysis for Roche s Pharmaceutical Manufacturing Network
Process Performance Analysis for Roche s Pharmaceutical Manufacturing Network Yiming Peng, Theo Koulis, Jens Lamerz, and Dan Coleman Nonclinical Biostatistics Genentech, A Member of the Roche Group 2017
More informationDaniel Y. Peng, Ph.D.
Using Control Charts to Evaluate Process Variability Daniel Y. Peng, Ph.D. Quality Assessment Lead Office of Process and Facility (OPF) OPQ/CDER/FDA PQRI 205 Annual Meeting North Bethesda, Maryland October
More informationStatistical Questions from CPV Monitoring of Bioreactor Data
Statistical Questions from CPV Monitoring of Bioreactor Data Craig Bernier Principal Statistician Design to Value and Quality Engineering Janssen Pharmaceutical Companies of Johnson and Johnson Individual
More informationPractical Applications of Statistical Methods Under 2011 FDA Process Validation Guidance
Practical Applications of Statistical Methods Under 2011 FDA Process Validation Guidance Abe Germansderfer Associate Director, Quality Control Gilead Sciences 2011 Process Validation Guidance In January
More informationProcess Performance Monitoring & needed engagement tools
Process Performance Monitoring & needed engagement tools September 17, 2014 Barbara Allen, Ph.D. Global Quality Systems Eli Lilly and Company Core Objective Safely & reliably manufacture quality medicines
More informationQUICK & DIRTY GRR PROCEDURE TO RANK TEST METHOD VARIABILITY
QUICK & DIRTY GRR PROCEDURE TO RANK TEST METHOD VARIABILITY Mike Mercer, Quality Engineering Specialist, 3M, St. Paul, MN Steve Cox, Lean Six Sigma Coach, 3M, St. Paul, MN Introduction One of the first
More informationQUALITY ASSESSMENT METHODS FOR NEW PRODUCT LAUNCHES: PROCESS VALIDATION LIFECYCLE
QUALITY ASSESSMENT METHODS FOR NEW PRODUCT LAUNCHES: PROCESS VALIDATION LIFECYCLE NAHEED SAYEED-DESTA APOTEX INC. CANADIAN SOCIETY FOR QUALITY 9 TH QUALITY CONGRESS SEPTEMBER 7-8, 2017 OUTLINE Introduction
More informationManaging Quality in Pharmaceutical Industry Using Six Sigma. Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA
Managing Quality in Pharmaceutical Industry Using Six Sigma Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA Outlines Pharmaceutical Manufacturing Process and Drug Product Quality. Process Excellence Approach
More informationProcess Capability: Practical Challenges to Implementation
Process Capability: Practical Challenges to Implementation [in pharmaceutical manufacturing] 33rd Quality & Productivity Research Conference Tempe, AZ June 16, 2016 Julia O Neill julia.oneill@tunnellconsulting.com
More informationPRESS INFORMATION No. 04/2014 August 2014
PRESS INFORMATION No. 04/2014 August 2014 Atris Information Systems GmbH. Kartaeuserstr. 49. D-79102 Freiburg Experience with System-supported Continued Process Verification by Peter Trochim Since January
More informationImplementation of Lifecycle Validation Practices at CMOs 1
Implementation of Lifecycle Validation Practices at CMOs 1 Rusty Morrison, CPIP Senior Consultant, CAI Consulting ISPE Boston Product Show, October 5, 2016 1 Based on the ISPE Discussion Paper Implementation
More informationProduct, Process Knowledge & SPC: PV Lifecycle Approach IFPAC January 2016, Arlington, VA
Product, Process Knowledge & SPC: PV Lifecycle Approach IFPAC January 2016, Arlington, VA Naheed Sayeed Manager, Technical Operations Process Validation, Apotex Inc. 1 Process Validation Life Cycle Stage
More informationBest Practices for OINDP Pharmaceutical Development Programs Leachables and Extractables. VIII. Quality Control and Specification Setting
Best Practices for OINDP Pharmaceutical Development Programs Leachables and Extractables VIII. Quality Control and Specification Setting PQRI Leachables & Extractables Working Group PQRI Training Course
More informationBest practices in Quality Metrics. Vivek Arora Partner, McKinsey & Company IPA CONFERENCE FEBRUARY 2019
Best practices in Quality Metrics Vivek Arora Partner, McKinsey & Company IPA CONFERENCE FEBRUARY 209 Management reviews & quality metrics have existed for a while Management review should provide assurance
More informationPrincipal approach to CPV :
Principal approach to CPV : Integration with Quality Systems & Operating Mechanisms J. Gampfer, Baxalta, Vienna Austria Baxalta Principal Approach to CPV J. Gampfer Page 1 Baxalta Principal Approach to
More informationPROCESS CAPABILITY AND PERFORMANCE IMPROVEMENT
PROCESS CAPABILITY AND PERFORMANCE IMPROVEMENT Chang-Sun Chin Construction Engineering and Management Program, Department of Civil and Environmental Engineering, University of Wisconsin, Madison, USA A
More informationUnderstanding and accounting for product
Understanding and Modeling Product and Process Variation Variation understanding and modeling is a core component of modern drug development. Understanding and accounting for product and process variation
More informationFuture of Pharmaceutical Quality and the Path to Get There
Future of Pharmaceutical Quality and the Path to Get There Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research 3rd PQRI/FDA Conference on Advancing
More informationQuality Metrics: A Regulatory Perspective
Quality Metrics: A Regulatory Perspective By Tara Gooen Bizjak, MBSci CDER Office of Policy for Pharmaceutical Quality Presented By Dr. Ademola Daramola US FDA Office of International Programs Indian Pharmaceutical
More informationQuality by Design: An Attempt to Jumpstart. Peter Calcott, Ph.D. President, Calcott Consulting
Quality by Design: An Attempt to Jumpstart Innovation Into the Manufacturing Process Peter Calcott, Ph.D. President, Calcott Consulting GMP in the 21 st Century Quality by Design (QbD) is part of Critical
More informationIdentifying and Controlling CPPs and CMAs
March 2018, BioPharm International Publication Identifying and Controlling CPPs and CMAs Thomas A. Little Ph.D. 2/22/2018 President/CEO Thomas A. Little Consulting, BioAssay Sciences 12401 N Wildflower
More informationFocused Trends from the FDA
Focused Trends from the FDA GXP INSPECTION READINESS Jolly Bhatia Sr. Director, QA Alnylam September 21, 2017 Credits: Tim Maines, Arya Tavana, John French, Roan Martin 13% of FDA Complete Response Letters
More informationPCI Pharmaceutical Consulting
PCI Pharmaceutical Consulting The Role of the QP: before & after Annex 16 Presented by: Karen Ginsbury For IFF, Denmark March 2016 Responsibility Authority Responsibility Authority Having the duty to perform
More informationMeasurement Systems Analysis
Measurement Systems Analysis Components and Acceptance Criteria Rev: 11/06/2012 Purpose To understand key concepts of measurement systems analysis To understand potential sources of measurement error and
More informationGraphical Tools - SigmaXL Version 6.1
Graphical Tools - SigmaXL Version 6.1 Basic and Advanced (Multiple) Pareto Charts Multiple Boxplots and Dotplots EZ-Pivot/Pivot Charts Multiple Normal Probability Plots (with 95% confidence intervals to
More informationMcKinsey ACQUA Assessment of Capabilities in Quality. Making the organization flow to Quality Excellence
McKinsey ACQUA Assessment of Capabilities in Quality Making the organization flow to Quality Excellence What is McKinsey Assessment of Quality Capabilities (ACQUA) and which impact can it bring to your
More informationProcess Validation Guidelines. by Pramote Cholayudth Thai Industrial Pharmacist Association (TIPA)
Process Validation Guidelines by Pramote Cholayudth cpramote2000@yahoo.com Thai Industrial Pharmacist Association (TIPA) September 19, 2016 1 2 Process Validation References Hierarchy Law Regulatory Guidelines
More informationProcess Capability and relationship to Quality management
Process Capability and relationship to Quality management Oct. 6, 2015 Barbara Allen, Ph.D. Global Quality Systems Eli Lilly and Company Core Objective Safely & reliably manufacture quality medicines for
More informationOBJECTIVE VISIONARY OF CMMI HIGH MATURITY PRACTICES WITH AGILE & DEVOPS
OBJECTIVE VISIONARY OF CMMI HIGH MATURITY PRACTICES WITH AGILE & DEVOPS NAME: Wael Philops TITLE: Manager QA & Risk ORGANIZATION: ITS AGENDA Who are we? ITS Development methodology Transformation To Agile
More informationPost Approval Changes & Product Lifecycle Management
Post Approval Changes & Product Lifecycle Management PDA West Coast Chapter Dinner Meeting Feb 22, 2018 Emma Ramnarine Sr. Director, Head Global Analytical Science & Technology Genentech/Roche 1 Globalization
More informationFour Innovative Methods to Evaluate Attribute Measurement Systems
Four Innovative Methods to Evaluate Attribute Measurement Systems Thomas Rust Reliability Engineer/Trainer Sept. 206 Saving More Lives Autoliv Global Footprint Japan RoA 0% Europe 7% 3% China 7% Sales
More informationContinuous Manufacturing: An Industry View
Novartis Pharmaceuticals Continuous Manufacturing: An Industry View Diane Zezza Novartis Pharmaceuticals FDA/PQRI Conference on Advancing Product Quality March 22, 2017 Where are we today? Continuous Manufacturing
More informationAn Introduction to Double Dragon Consulting
An Introduction to Double Dragon Consulting www.doubledragonconsulting.com About DDC Our Experience: - All dosage forms, aseptic processes, API manufacture, OTC - Remediation of 483 observations, Warning
More informationMetrics in Microbiology Monitoring Practices
Metrics in Microbiology Monitoring Practices Crystal Booth, M.M. Masters of Microbiology from North Carolina State University Former Associate Director of Microbiology at Novartis Metrics in Microbiology
More informationProcess Validation Guidelines. Report highlights 23 rd February 2018
Process Validation Guidelines Report highlights 23 rd February 2018 Process validation is an important element of pharmaceutical quality system An effective system provides assurance of the continued capability
More informationInstructor Info: Dave Tucker, LSSMBB ProModel Senior Consultant Office:
Instructor Info: Dave Tucker, LSSMBB ProModel Senior Consultant Office: 321.567.5642 dtucker@promodel.com 1 Understand how simulation models can be utilized within the DMAIC approach Examine a completed
More informationThe Power of Data to Accelerate Development of Robust & Scalable Manufacturing Processes
The Power of Data to Accelerate Development of Robust & Scalable Manufacturing Processes Susan Abu-Absi Director, Manufacturing Sciences & Technology Bristol-Myers Squibb Devens, MA USA May 11, 2016 1
More informationCPV/OPV PROCESS AND DECISION MAKING FOR LARGE MOLECULE DRUG SUBSTANCE: CASE STUDY
CPV/OPV PROCESS AND DECISION MAKING FOR LARGE MOLECULE DRUG SUBSTANCE: CASE STUDY Bethany Rexing bustardbe@lilly.com Eli Lilly and Company PRESENTATION OUTLINE 1. LILLY S VALIDATION LIFECYCLE MODEL 2.
More informationFDA s Draft Guidance Request for Quality Metrics: What All Drug and Biologics Manufacturers Need to Know June 2017
FDA s Draft Guidance Request for Quality Metrics: What All Drug and Biologics Manufacturers Need to Know June 2017 Discussion Topics Quality Concepts The Journey The Guidance Details Industry Responses
More information2 Days Workshop on Current issues in assuring data integrity in life sciences
WORLD COMPLIANCE SEMINARS SPEAKER:- CHINMOY ROY 2 Days Workshop on Current issues in assuring data integrity in life sciences 04-05 -OCT -2017 Location 1 Boston,MA 14-15 -NOV -2017 Location 2 San Diego
More information2 Day Seminar Assuring Data Integrity in the Life Science industry. Manufacturers
2 Day Seminar Assuring Data Integrity in the Life Science industry Manufacturers 12 RAPS CREDITS Location 1: Apr 06 07 Boston Location 2: Apr 20 21 San Francisco, CA Seminar One Registration $ 1195 06-Apr,
More informationClick to edit Master title style
Measuring Performance, Driving Excellence Click to edit Master title style ISPE Nordic, Stockholm WTC November 26 th 2015 Dr. Nuala Calnan, Research Fellow, Dublin Institute of Technology 11/26/2015 1
More informationStrategies for Improvement of Process Control
Strategies for Improvement of Process Control Michael V. Petrovich Luftig & Warren International National Manufacturing Week March 2000 Presentation Objectives Expand the concept of process control beyond
More informationCurrent Regulatory Considerations and Challenges for Continuous Manufacturing of Pharmaceuticals
15th DIA Japan Annual Meeting 2018 Promoting Better Collaboration to Drive Global Health and Innovation in an Era of Medical and Scientific Transformation November 11-13, 2018 Tokyo Big Sight V5-S3 Current
More informationStatistics and Pharmaceutical Quality
Statistics and Pharmaceutical Quality Karthik Iyer (CQE, CSSBB) Senior Policy Advisor CDER/OC/OMPQ January 24 th, 2014 IFPAC * This presentation reflects the views of the author and should not be construed
More informationThe long anticipated draft of the FDA s
This article provides an overview of the draft guidance, the key changes in relation to the 1987 guidance, and reviews its potential impact on the current industry approaches to science- and risk-based
More informationKey Definitions 6/16/2015
Technology Transfer from a CDMO Perspective Joe Cobb, CPIP Director, Pharmaceutical Development Metrics Contract Services, a division of Mayne Pharma US 18-June-2015 Key Definitions CDMO Contract Development/Manufacturing
More informationProcess Monitoring Applying QbD Principles in a Biopharmaceutical Environment
WCBP 205- CASS Conference Washington DC, July-20 to 2, 205 Process Monitoring Applying QbD Principles in a Biopharmaceutical Environment Michael Kraus PhD MBB Process Science & Technical Operations Baxalta
More informationISPE S GUIDES AND HOW THEY APPLY TO CLEANING AND CLEANING VALIDATION
ISPE S GUIDES AND HOW THEY APPLY TO CLEANING AND CLEANING VALIDATION Stephanie A. Wilkins, PE ISPE NORDIC CLEANING VALIDATION CONFERENCE 20 April 2016 Objectives > ISPE s Risk-MaPP Guide and its impact
More informationProject Quality Management. For the PMP Exam using PMBOK
Project Quality Management For the PMP Exam using PMBOK Guide 5 th Edition PMI, PMP, PMBOK Guide are registered trade marks of Project Management Institute, Inc. Contacts Name: Khaled El-Nakib, PMP, PMI-RMP
More informationBuilding Quality Culture and Capabilities Jaidev S Rajpal Partner, McKinsey & Company IPA CONFERENCE FEBRUARY 2019
Building Quality Culture and Capabilities Jaidev S Rajpal Partner, IPA CONFERENCE FEBRUARY 2019 CULTURE MATTERS 1 Quality culture matters: Increasingly companies believe that culture matters; this is also
More informationISPE Annual Meeting 29 October 1 November 2017 San Diego, CA. FDA Perspective on the Use of Process Capability
FDA Perspective on the Use of Process Capability Chunsheng Cai, Ph.D. Office of Process and Facilities Office of Pharmaceutical Quality, CDER, FDA 2017 ISPE Annual Meeting & Expo Disclaimer This presentation
More informationBest Practices For Cleaning Validation in the Aseptic Environment SUMMARY OF OUTLINE
Best Practices For Cleaning Validation in the Aseptic Environment Vivienne Yankah, PhD, CQE sanofi pasteur Ltd. Toronto, Canada SUMMARY OF OUTLINE Review Regulatory Standards for CV Designing and Developing
More informationSix Sigma Black Belt Study Guides
Six Sigma Black Belt Study Guides 1 www.pmtutor.org Powered by POeT Solvers Limited. Overview of Six Sigma DMAIC Define Define the project targets and customer (internal and external) deliverables. Measure
More informationQUALITY ASSURANCE FROM A-Z ERICSSON POWER MODULES
QUALITY ASSURANCE FROM A-Z ERICSSON POWER MODULES Quality Assurance From A-Z Supplier / Component Qualification Product Design Verification of Quality and Reliability performance Handling of incoming material
More informationThe application of skip testing to drug substance manufacture
Arsgera / Shutterstock.com PAT SERIES The application of skip testing to drug substance manufacture Phil Borman, Simon Bate and Keith Freebairn GlaxoSmithKline Skip testing is a process employed to reduce
More informationLifecycle Product Quality Risk Management
Lifecycle Product Quality Risk Management Richard L. Friedman, M.S. Associate Director Office of Manufacturing and Product Quality Office of Compliance IFPAC Annual Meeting (Arlington, VA) January, 21-24,
More informationISPE Quality Metrics Program An Update
ISPE Quality Metrics Program An Update Diane Hagerty, Genentech / Roche Vice President, Global Quality Systems & Processes 17 September 2014 ISPE Quality Metrics Program Overview Quality Metrics Industry
More informationICH Q12 Perspectives: The Robust PQS
ICH Q12 Perspectives: The Robust PQS PQRI October 5 th, 2015 Mahesh Ramanadham, Pharm.D./MBA Branch Chief, Inspection Assessment Branch 2 Division of Inspection Assessment Office of Process and Facilities
More informationFor the PMP Exam using PMBOK. PMI, PMP, PMBOK Guide are registered trade marks of Project Management Institute, Inc.
For the PMP Exam using PMBOK Guide 5 th Edition PMI, PMP, PMBOK Guide are registered trade marks of Project Management Institute, Inc. 1 Contacts Name: Khaled El-Nakib, MSc, PMP, PMI-RMP URL: http://www.khaledelnakib.com
More informationQuality Assurance in nonregulated. pharmaceutical industry. Thomas Steckler
Quality Assurance in nonregulated research of the pharmaceutical industry Thomas Steckler The views expressed in this presentation are solely those of the individual authors, and do not necessarily reflect
More informationOffice of Pharmaceutical Quality Progress Update
Office of Pharmaceutical Quality Progress Update Michael Kopcha, Ph.D., R.Ph. Director Office of Pharmaceutical Quality CDER/FDA 2017 3 rd PQRI/FDA Conference on Advancing Product Quality March 22-24,
More informationImplementation of PAT for Real Time Release Testing. Mark Smith Process Analytical Sciences Group Pfizer, Cork
Implementation of PAT for Real Time Release Testing Mark Smith Process Analytical Sciences Group Pfizer, Cork PAT at Pfizer A key enabler for transformational strategies and new quality paradigms 9 Delivering
More informationMitigating Commercial Risks in Continuous Manufacturing Drug Product
Mitigating Commercial Risks in Continuous Manufacturing Drug Product Ian Leavesley Eli Lilly Indianapolis, Indiana Commercializing Continuous Processing in Pharma Boston, MA Jan 30 th Feb 1 st 2017 Outline
More informationOperational Opportunities in Continued Process Validation
Operational Opportunities in Continued Process Validation IFPAC 2015 Tamar Ben-Avi Director, Head of Pharmaceutical Technology Taro Pharmaceuticals, Haifa, Israel Content Introduction Continued Process
More informationICH Q9 An Industry Perspective: Ensuring Quality to Patients in a Risk-Based Regulatory Environment
ICH Q9 An Industry Perspective: Ensuring Quality to Patients in a Risk-Based Regulatory Environment Thomas Schultz, Ph.D. Director, Regulatory Sciences Johnson & Johnson September 12, 2007 Presentation
More informationPreview of New PDA Technical Report on Process Validation
PCMO (Paradigm Change to Manufacturing Operations) Process Validation and Verification: A Life- cycle Approach Preview of New PDA Technical Report on Process Validation Peter Levy PL Consulting, LLC peter@plevyconsulting.com
More informationEVOLVING TRENDS IN THE USE OF STATISTICS FOR PROCESS VALIDATION IVT 3 RD ANNUAL STATISTICS IN VALIDATION JUNE 20-22, 2017
EVOLVING TRENDS IN THE USE OF STATISTICS FOR PROCESS VALIDATION IVT 3 RD ANNUAL STATISTICS IN VALIDATION JUNE 20-22, 2017 KATHERINE GIACOLETTI PARTNER, SYNOLOSTATS LLC OUTLINE Background How we got to
More informationNovartis E2E CM case study
Technical R&D/CHAD CM Unit Novartis E2E CM case study Markus Krumme, CM Unit Head Cambridge, MA September 26, 2016 Continuous Manufacturing at Novartis Basel ~300 m 2 productive area, 2 upstream trains,
More informationEnsuring An Effective Quality System. M. Kowolenko, Ph.D. SVP, Biopharmaceutical Operations & Technology
Ensuring An Effective Quality System M. Kowolenko, Ph.D. SVP, Biopharmaceutical Operations & Technology Role of the Quality Unit Compliance with all relevant regulations and commitments made in license
More informationFDA Quality Metrics Guidance
FDA Quality Metrics Guidance Marlène García Swider, Ph.D., CQM, CSSBB Institute of Validation Technology Quality Metrics Conference February 22 24, 2016 Coronado Island, San Diego, CA Personal Claim This
More informationICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management
ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Keith O. Webber, Ph.D. Sr. Director, Global Regulator Affairs Rx Perrigo Company, plc Q U A L I T Y A F F
More informationIPA Quality Forum Reflections on the Journey so far
IPA Quality Forum Reflections on the Journey so far India Pharmaceutical Forum 2018 23rd Feb 2018 The IPA Quality forum was formed with a vision of helping the Indian pharma industry achieve excellence
More informationPROCESS VALIDATION ANSM 2015 FDA 2011
PROCESS VALIDATION ANSM 2015 FDA 2011 PBE-Expert Inc CANADA Training Company Agreement CPMT #0059104 Qualified Consultant At the measure 2 of the Levier Program PBE, Training Company Agreement CPMT #0059104
More informationAn Industry Perspective: The Complexity of Postapproval CMC Changes and Proposed Regulatory Strategies. SPEAKER: Suzanne Murray Biogen
An Industry Perspective: The Complexity of Postapproval CMC Changes and Proposed Regulatory Strategies SPEAKER: Suzanne Murray Biogen Contents 1. BioPhorum Operations Group (BPOG) and the Post-approvals
More informationC O N T E N T S. Brief introduction to Six-Sigma. Case development and hands-on exercises. Conclusions. August 9, 2013 Santiago, Chile
TheApplicationof Six-Sigma DMAIC to a Distribution System Edgardo J. Escalante, Ph.D. ITESM México Pan-American Advanced Studies Institute on Modeling, Simulation and Optimization of Globalized Physical
More informationPQLI Engineering Controls and Automation Strategy
J Pharm Innov (2008) 3:88 94 DOI 10.1007/s12247-008-9031-5 PRODUCT QUALITY LIFECYCLE IMPLEMENTATION (PQLI) INNOVATIONS PQLI Engineering Controls and Automation Strategy Ray Bolton Stephen Tyler Published
More informationQuality by Design Facilitating Real Time Release (RTR) Practical Challenges and Opportunities during RTR Implementation
Quality by Design Facilitating Real Time Release (RTR) Practical Challenges and Opportunities during RTR Implementation Carl E. Longfellow Ph.D., Senior Director, New Product and Process Development, Discussion
More informationLeft to Our Own Devices Design Control & Risk Management Strategies for Combination Products
Left to Our Own Devices Design Control & Risk Management Strategies for Combination Products DR. RICK WEDGE 12 MAR 2018 Overview Definitions Current Regulatory Landscape Design Controls Risk Management
More informationAn Introduction to Double Dragon Consulting
An Introduction to Double Dragon Consulting www.doubledragonconsulting.com 1 June 2012 About DDC Our Experience: All dosage forms, aseptic processes, OTC Remediation of 483 observations, warning letters,
More informationTech-Clarity Insight: Quality Risk Management in Life Sciences. Preventing Failures, Protecting Patient Health
Tech-Clarity Insight: Quality Risk Management in Life Sciences Preventing Failures, Protecting Patient Health Tech-Clarity, Inc. 2010 Table of Contents Table of Contents... 2 Executive Overview... 3 Mitigating
More informationAdvantages, Opportunities & Challenges of Adopting the Post Approval Change Management Plan (PACMP)
Advantages, Opportunities & Challenges of Adopting the Post Approval Change Management Plan (PACMP) Quality Forum September 2018 roger nosal, Vice President & Head Worldwide Safety & Regulatory - Global
More informationEnsuring Quality & Regulatory Compliance when Collaborating with a Service Provider
DPT Thought Leadership Issue 2 Ensuring Quality & Regulatory Compliance when Collaborating with a Service Provider I N T R O D U C T I O N In recent years, the pharmaceutical industry has given greater
More informationA COMPARATIVE FRAMEWORK BETWEEN NEW PRODUCT & LEGACY PRODUCT PROCESS VALIDATION
A COMPARATIVE FRAMEWORK BETWEEN NEW PRODUCT & LEGACY PRODUCT PROCESS VALIDATION By Mark Mitchell, Principal Consultant, Process and Engineering, Pharmatech Associates, Inc. PHARMATECH WHITE PAPER.DOCX
More informationQ10 PHARMACEUTICAL QUALITY SYSTEM
Q10 PHARMACEUTICAL QUALITY SYSTEM This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights
More informationLifecycle Approach to Process Validation
Lifecycle Approach to Process Validation Best Practices and Strategies July 19 th, 2016 Patrick Donohue, Drug Product Development, Janssen R&D Disclaimer The contents of this presentation are my personal
More informationPQLI Control Strategy Model and Concepts
J Pharm Innov (008) :95 104 DOI 10.1007/s147-008-905-1 PRODUCT QUALITY LIFECYCLE IMPLEMENTATION (PQLI) INNOVATIONS PQLI Control Strategy Model and Concepts Bruce Davis Line Lundsberg Graham Cook Published
More informationROOT CAUSE ANALYSIS. 10+ unique perspectives on CAPA systems implementation and management. Sponsors:
5TH SIGNAL DETECTION, ROOT CAUSE ANALYSIS & JANUARY 22-23, 2015 KEY BRIDGE MARRIOTT ARLINGTON, VA Prevent Non-Compliance and Achieve Successful Root Cause Analyses and CAPA Systems Implementation from
More informationChallenges Integrating Regulatory Filings and Pre-Approval Inspection with the Expectations of Current Regulatory Guidance
Challenges Integrating Regulatory Filings and Pre-Approval Inspection with the Expectations of Current Regulatory Guidance Tony Mire-Sluis Vice President, North America, Singapore, Abingdon, Contract and
More informationProcess Validation Lifecycle Approach: A Return to Science
Process Validation Lifecycle Approach: A Return to Science PDA New England Chapter / ISPE Boston Chapter Joint Meeting September 16, 2015 Woburn, MA Rusty Morrison Principal Consultant, CAI Consulting
More informationPDA Quality Culture Program Overview
PDA Quality Culture Program Overview Are you ready to assess your site s quality culture? Cylia Chen, PDA Quality Culture team PDA SoCal Chapter Nov. 2016 1 What is FDA (and industry) Striving for? A maximally
More informationDr. Earl Dye CMC/GMP Considerations for Expedited Development Programs
Dr. Earl Dye CMC/GMP Considerations for Expedited Development Programs Earl Dye is Director of Technical Regulatory Policy in Genentech s Washington, DC Regulatory Affairs Office, and is the FDA Liaison
More informationTransforming your Historical Metrics to a Futuristic State
Transforming your Historical Metrics to a Futuristic State Forrest W. Breyfogle III CEO, Smarter Solutions, Inc. SmarterSolutions.com +1 512.918.0280 Forrest@SmarterSolutions.com Copyright 1992 2014. All
More informationApplying Statistical Techniques to implement High Maturity Practices At North Shore Technologies (NST) Anand Bhatnagar December 2015
Applying Statistical Techniques to implement High Maturity Practices At North Shore Technologies (NST) Anand Bhatnagar December 2015 For our audience some Key Features Say Yes when you understand Say No
More informationCell Therapy Product Manufacturing Considerations. July 17, 2017 CMC Strategy Forum Mo Heidaran, Ph.D.
Cell Therapy Product Manufacturing Considerations July 17, 2017 CMC Strategy Forum Mo Heidaran, Ph.D. Office of Tissues and Advanced Therapies FDA/CBER Overview Establishing Manufacturing Control Applying
More information